- RIASTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
- RIASTAP is not indicated for dysfibrinogenemia
RiaSTAP®
Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.
Product Information
Known anaphylactic or severe systemic reactions to human plasma-derived products.
- Dose (mg/kg body weight) = [Target level (mg/dL) - measured level (mg/dL)/ 1.7 (mg/dL per mg/kg body weight)
- Dose when fibrinogen level is unknown: 70 mg/kg body weight
- Monitoring of patient’s fibrinogen level is recommended during treatment. A target fibrinogen level of 100 mg/dL should be maintained until hemostasis is obtained.
Dose (mg/kg body weight) =
[Target level (mg/dL) - measured level (mg/dL)]
1.7 (mg/dL per mg/kg body weight)
- Administer RIASTAP at room temperature by slow intravenous injection at a rate not exceeding 5 mL per minute.
- RIASTAP is available as a single-dose vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution. The actual fibrinogen potency for each lot is printed on the vial label and carton.
- Before administration, filter reconstituted RIASTAP solution with a 17-micron filter (not supplied) into an appropriate syringe.
